BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 26662468)

  • 1. Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey.
    Tsushima Y; Ishiguchi T; Murakami T; Hayashi H; Hayakawa K; Fukuda K; Korogi Y; Sugimoto H; Takehara Y; Narumi Y; Arai Y; Kuwatsuru R; Yoshimitsu K; Awai K; Kanematsu M; Takagi R
    Jpn J Radiol; 2016 Feb; 34(2):130-9. PubMed ID: 26662468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical administration of intravenous contrast media in children: screening, prophylaxis, administration and treatment of adverse reactions.
    Maloney E; Iyer RS; Phillips GS; Menon S; Lee JJ; Callahan MJ
    Pediatr Radiol; 2019 Apr; 49(4):433-447. PubMed ID: 30923875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media.
    Rees O; Agarwal SK
    Clin Radiol; 2010 Aug; 65(8):636-41. PubMed ID: 20599066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of contrast media: an update.
    ten Dam MA; Wetzels JF
    Neth J Med; 2008 Nov; 66(10):416-22. PubMed ID: 19011267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kidney and iodinated and gadolinium-based contrast agents].
    Clément O; Faye N; Fournier L; Siauve N; Frija G
    J Radiol; 2011 Apr; 92(4):291-8. PubMed ID: 21549885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
    Canga A; Kislikova M; Martínez-Gálvez M; Arias M; Fraga-Rivas P; Poyatos C; de Francisco AL
    Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: A survey of the use of gadolinium-based contrast agents in Ghana.
    Piersson AD; Gorleku PN
    Radiography (Lond); 2017 Nov; 23(4):e108-e113. PubMed ID: 28965904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital.
    Miki Y; Isoda H; Togashi K
    J Magn Reson Imaging; 2009 Dec; 30(6):1364-5. PubMed ID: 19937936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):871-5, vii. PubMed ID: 19744601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Safety Guidelines on the Use of Iodinated Contrast Material: Conundrum Continued.
    Nijssen EC; Nelemans PJ; Rennenberg RJ; van Ommen V; Wildberger JE
    Invest Radiol; 2018 Oct; 53(10):616-622. PubMed ID: 29762257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis and management of high-risk patients.
    Altun E; Semelka RC; Cakit C
    Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].
    Varela CU; Prieto-Rayo JC
    Rev Med Chil; 2014 Dec; 142(12):1565-74. PubMed ID: 25693439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk.
    Nicholas BA; Vricella GJ; Smith M; Passalacqua M; Gulani V; Ponsky LE
    Can J Urol; 2012 Feb; 19(1):6074-80. PubMed ID: 22316507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction].
    Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K
    Nihon Jinzo Gakkai Shi; 2008; 50(7):858-60. PubMed ID: 19069139
    [No Abstract]   [Full Text] [Related]  

  • 16. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines.
    Stacul F; van der Molen AJ; Reimer P; Webb JA; Thomsen HS; Morcos SK; Almén T; Aspelin P; Bellin MF; Clement O; Heinz-Peer G;
    Eur Radiol; 2011 Dec; 21(12):2527-41. PubMed ID: 21866433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis.
    Weinreb JC; Kuo PH
    Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NSF: still relevant.
    Thomsen HS
    J Magn Reson Imaging; 2014 Jul; 40(1):11-2. PubMed ID: 24990765
    [No Abstract]   [Full Text] [Related]  

  • 20. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
    Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
    Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.